Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc

<< Previous

Bullboard Posts

Next >>

Post by Francine01on Jul 19, 2019 3:44pm

149 Views

Post# 29941323

Acuitas / Peizer owned 8,650,000 or 10.58% as at October.

As per wikipdia:
Terren Scott Peizer, dubbed the "Zelig of Wall Street"^[1]^[2], is an International Financier and Chairman of Los Angeles-based investment company, Acuitas Group Holdings (AGH). Peizer is Founder and Chairman of the three Acuitas companies, and is CEO of Catasys, Inc. and Crede Capital Group. He has been called "One of Wall Street’s top players" (...)
Peizer's investment philosophy was taking shape during these years, which according to Peizer, was to "Invest in situations where you tip the playing field in your favor and Invest in companies with low market caps but with the ability to change the way its industry does things."^[10] Peizer applied his financial acumen and structuring expertise to minimize his investment at risk, but allow for exponential returns.

<< Previous

Bullboard Posts

Next >>

2024, a breakthrough year for silver